Research shows vitamin D does not reduce colon cancer risk in most people with Lynch syndrome, according to a 2026 study of 2,351 Lynch syndrome carriers followed for 7.2 years. However, among people carrying the PMS2 gene mutation specifically, each increase in vitamin D concentration was associated with a 27% lower risk of developing precancerous growths or cancer, suggesting vitamin D’s protective effect may depend on which genetic mutation a person carries.
Researchers studied 2,351 people with Lynch syndrome, a genetic condition that greatly increases colon cancer risk, to see if vitamin D could help protect them. According to Gram Research analysis, higher vitamin D levels did not reduce the risk of developing precancerous growths or colon cancer in most Lynch syndrome carriers over a 7-year period. However, the study found an interesting exception: people with a specific genetic mutation called PMS2 showed a 27% lower risk of developing these growths when they had higher vitamin D levels. This finding suggests that vitamin D’s protective effects may depend on which specific gene mutation a person carries.
Key Statistics
A 2026 cohort study of 2,351 Lynch syndrome carriers found that 27.5% developed precancerous growths or colorectal cancer over a median follow-up of 7.2 years, with no overall protective effect from higher vitamin D levels.
Among PMS2 mutation carriers in the study, a 10 nmol/L increase in vitamin D concentration was associated with a 27% lower risk of developing colorectal neoplasms, suggesting a gene-specific protective effect.
In the 2026 Lynch syndrome study, people with deficient vitamin D levels (below 50 nmol/L) showed no increased cancer risk compared to those with sufficient levels, contradicting findings from general population studies.
The Quick Take
- What they studied: Whether higher vitamin D levels in the blood could reduce the risk of developing precancerous growths or colon cancer in people with Lynch syndrome, a genetic condition that makes colon cancer much more likely.
- Who participated: 2,351 people with Lynch syndrome from two large research registries were followed for an average of 7.2 years. Lynch syndrome is an inherited genetic condition affecting how the body repairs DNA damage.
- Key finding: Overall, vitamin D levels made no difference in colon cancer risk for most Lynch syndrome carriers. However, among the 647 people who developed precancerous growths or cancer during the study, those with a PMS2 gene mutation showed a 27% lower risk when vitamin D levels were higher.
- What it means for you: If you have Lynch syndrome, taking vitamin D supplements based on general population studies may not provide the same protection. However, if you carry the PMS2 mutation specifically, maintaining adequate vitamin D levels might offer some benefit. Talk with your doctor about your specific genetic mutation and whether vitamin D supplementation makes sense for your situation.
The Research Details
This was a cohort study, meaning researchers followed a large group of people over time and tracked what happened to them. The study included 2,351 people with Lynch syndrome from two major research registries. Researchers measured vitamin D levels in blood samples using a precise laboratory method called isotope-dilution Liquid Chromatography-tandem Mass Spectrometry, which is one of the most accurate ways to measure vitamin D.
Participants were followed for an average of 7.2 years, during which researchers tracked who developed precancerous growths (adenomas and serrated lesions) or colorectal cancer. The researchers used statistical methods to compare cancer risk between people with different vitamin D levels, while accounting for other factors that might affect cancer risk like age, sex, and whether someone had previously had precancerous growths.
The study looked at vitamin D levels in three categories: deficient (very low), sufficient (moderate), and optimal (high). Researchers also examined whether the protective effect of vitamin D differed depending on which specific gene mutation each person carried, since Lynch syndrome can result from mutations in different genes.
This research approach is important because previous studies in the general population suggested vitamin D might protect against colon cancer. However, Lynch syndrome is a special case because people with this condition have a much higher baseline risk of colon cancer due to their genetic mutation. It was unclear whether vitamin D would provide the same protection for this high-risk group. By studying Lynch syndrome carriers specifically, researchers could determine whether findings from the general population apply to people with this genetic condition.
This study has several strengths: it included a large number of participants (2,351), used a precise laboratory method to measure vitamin D, and followed people for several years to track actual cancer development. The study was published in a peer-reviewed journal focused on cancer research. However, the study is observational, meaning researchers observed what happened naturally rather than randomly assigning people to take vitamin D or placebo. This means we cannot be completely certain that vitamin D itself caused the differences observed, as other unmeasured factors could play a role.
What the Results Show
During the 7.2-year follow-up period, 647 out of 2,351 Lynch syndrome carriers (27.5%) developed precancerous growths or colorectal cancer. When researchers compared people with deficient vitamin D levels to those with sufficient levels, there was no meaningful difference in cancer risk. Similarly, people with optimal vitamin D levels did not have lower cancer risk compared to those with sufficient levels. When researchers looked at whether each small increase in vitamin D concentration mattered, they found no overall protective effect across the entire group.
These results were surprising because they contradicted findings from studies of the general population, where higher vitamin D levels have been associated with lower colon cancer risk. This suggests that the relationship between vitamin D and colon cancer may be different for people with Lynch syndrome compared to people without this genetic condition.
The most interesting finding came when researchers looked separately at people with different types of Lynch syndrome mutations. Among the 647 people who developed cancer or precancerous growths, those carrying the PMS2 gene mutation showed a different pattern. For every 10 nmol/L increase in vitamin D concentration (roughly equivalent to a 4 ng/mL increase), PMS2 carriers had a 27% lower risk of developing precancerous growths or cancer.
The study examined whether vitamin D’s effect differed based on age, sex, previous cancer history, and geographic region, but found no meaningful differences in these subgroups for the overall population. The PMS2 finding was the only subgroup where vitamin D appeared to have a protective effect. This suggests that the specific genetic mutation a person carries may be more important than other demographic factors in determining whether vitamin D offers protection.
Previous research in the general population has consistently shown that higher vitamin D levels are associated with lower colorectal cancer risk, with some studies suggesting a 20 to 30% reduction in risk. This is the first study to specifically examine this relationship in Lynch syndrome carriers. The overall null finding (no protective effect) suggests that the genetic mutations causing Lynch syndrome may override or interfere with vitamin D’s protective mechanisms. The PMS2-specific finding is new and has not been previously reported, making it an important area for future research.
This study has several important limitations. First, it is observational, so we cannot prove that vitamin D itself caused the differences in cancer risk. Second, vitamin D levels were measured only once at the beginning of the study, so researchers could not track changes in vitamin D levels over time. Third, the study did not include information about vitamin D supplementation or sun exposure, which affect vitamin D levels. Fourth, the PMS2 finding involved a smaller subgroup and needs to be confirmed in future studies before drawing firm conclusions. Finally, the study included mostly people of European ancestry, so results may not apply equally to other racial and ethnic groups.
The Bottom Line
For most Lynch syndrome carriers, current evidence does not support taking vitamin D supplements specifically to reduce colon cancer risk, though maintaining adequate vitamin D for overall bone and immune health remains important. For people with the PMS2 mutation specifically, maintaining adequate vitamin D levels (at least 50 nmol/L or 20 ng/mL) may offer some additional benefit, though more research is needed to confirm this. All Lynch syndrome carriers should follow recommended colorectal cancer screening protocols, which are the most effective way to prevent cancer in this population. Discuss your specific genetic mutation and vitamin D status with your doctor to determine the best approach for your individual situation.
This research is most relevant to people with Lynch syndrome and their families, as well as genetic counselors and doctors who care for Lynch syndrome patients. People with the PMS2 mutation specifically should pay attention to this finding. People without Lynch syndrome should not assume these results apply to them, as vitamin D may still offer protection in the general population.
If vitamin D does provide protection for PMS2 carriers, the benefit would likely develop gradually over months to years, not immediately. The study followed people for an average of 7.2 years, and the protective effect was observed over this longer timeframe. Maintaining consistent vitamin D levels over time appears more important than short-term supplementation.
Frequently Asked Questions
Does vitamin D prevent colon cancer in people with Lynch syndrome?
For most Lynch syndrome carriers, research shows vitamin D does not reduce colon cancer risk. However, people with the PMS2 mutation showed a 27% lower risk with higher vitamin D levels in a 2026 study of 2,351 carriers, suggesting the effect may depend on genetic mutation type.
Should I take vitamin D supplements if I have Lynch syndrome?
Talk with your doctor about your specific genetic mutation. While general vitamin D supplementation for bone and immune health remains important, current evidence does not support taking it specifically to prevent colon cancer in most Lynch syndrome carriers. PMS2 carriers may benefit from maintaining adequate levels.
What vitamin D level should Lynch syndrome carriers aim for?
The study defined sufficient vitamin D as 50 to 75 nmol/L (20 to 30 ng/mL). Maintaining levels above 50 nmol/L appears reasonable for overall health, though higher levels did not provide additional cancer protection in most Lynch syndrome carriers.
Is this study relevant to people without Lynch syndrome?
This study specifically examined Lynch syndrome carriers and may not apply to the general population. Previous research suggests vitamin D may protect against colon cancer in people without Lynch syndrome, so discuss vitamin D status with your doctor based on your individual risk factors.
What should Lynch syndrome carriers do to prevent colon cancer?
The most effective strategy is following recommended colonoscopy screening protocols, which can detect and remove precancerous growths before they become cancer. Vitamin D supplementation may offer additional benefit for PMS2 carriers, but screening remains the primary prevention strategy.
Want to Apply This Research?
- Track quarterly vitamin D blood test results (measured as 25-hydroxyvitamin D in nmol/L or ng/mL) alongside any precancerous growths or cancer diagnoses found during colonoscopy screening. Set a target of maintaining vitamin D levels above 50 nmol/L (20 ng/mL) and note any changes in these levels.
- If you have Lynch syndrome, especially with a PMS2 mutation, use the app to set reminders for regular vitamin D testing and to log your vitamin D supplementation if your doctor recommends it. Track sun exposure and dietary sources of vitamin D (fatty fish, fortified milk, egg yolks) to help maintain consistent levels.
- Create a long-term tracking dashboard showing vitamin D levels over time alongside colonoscopy results and any precancerous growths found. Set annual reminders to discuss vitamin D status with your doctor, particularly if you carry the PMS2 mutation. Monitor adherence to both vitamin D supplementation (if recommended) and cancer screening protocols.
This article summarizes research findings and should not be interpreted as medical advice. People with Lynch syndrome should work with their healthcare provider and genetic counselor to develop personalized cancer prevention and screening strategies based on their specific genetic mutation and individual risk factors. Vitamin D supplementation decisions should be made in consultation with a doctor. This research is preliminary regarding PMS2 carriers and requires confirmation in future studies before clinical recommendations can be made.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.